@article{ba130d15541040c1a7fb3169ff06a174,
title = "Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation",
abstract = "Purpose: HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) carries a favorable prognosis for patients, yet nearly 30% of patients will experience disease relapse. We sought to detail patterns of failure, associated salvage therapy, and outcomes for patients with recurrent HPV-positive OPSCC. Methods and materials: This is a single institution retrospective study of patients with recurrent HPV-positive OPSCC irradiated from 2002 to 2014. The primary study outcome was overall survival (OS, calculated using the Kaplan-Meier method). Secondary aims included patterns of first failure with descriptive details of salvage therapy. Solitary recurrences were defined as initial presentation of recurrence in a single site (primary, neck or oligometastatic), and multi-site was defined as local and regional and/or multiple sites of distant recurrence. Survival outcomes were compared using the log-rank test. Results: The cohort consisted of 132 patients. The median follow-up was 59 months for surviving patients. Estimated 2-year and 5-year OS rates were 47% and 32%, respectively. Comparative 2-year and 5-year OS rates were 65% and 46% versus 19% and 9% for the solitary group and multi-site group, respectively (p < .001). Conclusions: Patients with recurrent HPV-positive OPSCC experience 5-year survival of approximately 32%. However, patients with a “solitary” recurrence including disease at the primary site, neck or oligometastatic site have more favorable long-term outcomes.",
keywords = "HPV-positive, Head and neck cancer, Oligometastatic disease, Oropharyngeal cancers, Patient outcomes, Patterns of failure, Salvage therapy, Squamous cell carcinoma",
author = "Christopherson, {Kaitlin M.} and Moreno, {Amy C.} and Baher Elgohari and Neil Gross and Renata Ferrarotto and Mohamed, {Abdallah Sherif Radwan} and {Brandon Gunn}, G. and Goepfert, {Ryan P.} and Mott, {Frank E.} and Shah, {Shalin J.} and {David Fuller}, C. and Reddy, {Jay P.} and Frank, {Steven J.} and Morrison, {William H.} and Jack Phan and Rosenthal, {David I.} and Garden, {Adam S.}",
note = "Funding Information: Funding sources and financial disclosures: Dr. Fuller receives funding via the multidisciplinary Stiefel Oropharyngeal Research Fund of The University of Texas MD Anderson Cancer Center Charles and Daneen Stiefel Center for Head and Neck Cancer, as well as a multi-site National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679) and the NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825). Dr. Gunn received a philanthropic gift from the Family of Paul W. Beach. Drs. Mohamed and Fuller received funding support from the National Institutes of Health (NIH)/National Institute for Dental and Craniofacial Research (1R01DE025248/R56DE025248). NIH/NCI (R21CA226200), and the NIH/NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148). Dr. Fuller received grant and/or salary support from: the Andrew Sabin Family Foundation; The Mike Hogg Foundation; National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787-01); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); the NIH/National Cancer Institute Head and Neck Specialized Programs of Research Excellence Developmental Research Program Award (P50CA097007); a Paul Calabresi Clinical Oncology Program Award (K12 CA088084); a General Electric Healthcare/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award; an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; the Center for Radiation Oncology Research at MD Anderson Cancer Center Seed Grant; and the MD Anderson Institutional Research Grant (IRG) Program. Dr. Fuller has received speaker honoraria, grant support, and travel funding from Elekta AB. Funding Information: Dr. Frank reports personal fees from Varian, grants and personal fees from C4 Imaging, grants from Eli Lilly, grants from Elekta, grants and personal fees from Hitachi, other from Breakthrough Chronic Care, personal fees from Augmenix, personal fees from National Comprehensive Cancer Center (NCCN), outside the submitted work. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",
year = "2021",
month = feb,
doi = "10.1016/j.oraloncology.2020.105125",
language = "English (US)",
volume = "113",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
}